In multiple myeloma (MM), OC exerts its effects by inhibiting MIP-1α/CCL3 signaling, thereby disrupting the adhesion of MM cells to stromal components and reducing IL-6 production [211]. Here, CCL3 is linked to plasma cell myeloma.